Jiangbin Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiangbin Ye has a total of 393 co-authors. Here are the top co-authors by number of shared publications:
- Haowen Jiang
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
79 shared publications - Bo He
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
76 shared publications - Yang Li
Department of Radiation Oncology, Stanford University
76 shared publications - Albert M. Li
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
72 shared publications - Meng-Ning Zhou
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
70 shared publications - Clifford Jiajun He
School of Medicine University of California San Diego La Jolla California USA
52 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (27) , eaed6463
A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC
Cysteine metabolism plays a crucial role in the growth and survival of non–small cell lung cancer (NSCLC), although the mechanisms governing its regulation are not fully understood. Here, we demonstrate that the RNA demethylase FTO is a therapeutic target that drives cysteine metabolism in NSCLC cells. Genetic or pharmacologic inhibition of FTO reduced cystine uptake and transsulfuration activity, leading to depleted intracellular glutathione, elevated reactive oxygen species (ROS), and ROS-mediated DNA damage and cell death. Mechanistically, FTO promotes the expression of the cystine uptake transporter SLC7A11 and the transsulfuration enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CTH) to promote NSCLC cystine uptake, transsulfuration activity, and survival. FTO inhibition increased lipid peroxidation, reduced tumor growth, and resulted in additive therapeutic benefit in combination with radiotherapy in multiple NSCLC xenograft models. Collectively, our study reveals a role for FTO in cysteine metabolism and highlights the therapeutic potential of targeting cancer epitranscriptomics and cysteine metabolism for NSCLC therapy.
- 3 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (27) , eaed6463
Open AccessA targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC
Cysteine metabolism plays a crucial role in the growth and survival of non–small cell lung cancer (NSCLC), although the mechanisms governing its regulation are not fully understood. Here, we demonstrate that the RNA demethylase FTO is a therapeutic target that drives cysteine metabolism in NSCLC cells. Genetic or pharmacologic inhibition of FTO reduced cystine uptake and transsulfuration activity, leading to depleted intracellular glutathione, elevated reactive oxygen species (ROS), and ROS-mediated DNA damage and cell death. Mechanistically, FTO promotes the expression of the cystine uptake transporter SLC7A11 and the transsulfuration enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CTH) to promote NSCLC cystine uptake, transsulfuration activity, and survival. FTO inhibition increased lipid peroxidation, reduced tumor growth, and resulted in additive therapeutic benefit in combination with radiotherapy in multiple NSCLC xenograft models. Collectively, our study reveals a role for FTO in cysteine metabolism and highlights the therapeutic potential of targeting cancer epitranscriptomics and cysteine metabolism for NSCLC therapy.
- Open Access
- 14 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (20) , 2328-2343
DHODH as a targetable metabolic Achilles’ heel for chemotherapy-resistant B-ALL
Relapse remains a major barrier to survival in B-cell acute lymphoblastic leukemia (B-ALL). Both activation of B-cell signaling pathways and increased glucose consumption have been linked to chemoresistance and relapse risk. In this study, we connect these observations by showing that B-ALL cells with active mTOR signaling, marked by high phosphorylated ribosomal protein S6 (pS6+), are glucose dependent. Isotope tracing confirms that pS6+ cells are highly glycolytic and rely on glucose for de novo nucleotide synthesis. Uridine, but not other purines or pyrimidines, rescue pS6+ cells from glucose deprivation, highlighting uridine as essential for survival. Active mammalian target of rapamycin (mTOR) signaling in pS6+ cells drives de novo pyrimidine synthesis by activating carbamoyl phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyzes the initial steps of de novo pyrimidine synthesis. Inhibiting signaling abolishes glucose dependency and CAD phosphorylation. Primary pS6+ cells express high levels of pyrimidine synthesis proteins, including dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in pyrimidine synthesis. Increased DHODH expression correlates with relapse and poor event-free survival. Most B-ALL molecular subtypes exhibit DHODH activity. BAY-2402234, a DHODH inhibitor, effectively kills pS6+ cells in vitro, with 50% inhibitory concentration values correlating with pS6 signaling strength across 14 xenografts derived from patients with B-ALL. In vivo, DHODH inhibition prolongs survival and reduces leukemia burden in pS6+ B-ALL models. Together, these findings link active signaling to pyrimidine dependency and relapse risk, highlighting DHODH inhibition as a promising therapeutic strategy for chemotherapy-resistant B-ALL.
- 14 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (20) , 2328-2343
Open AccessDHODH as a targetable metabolic Achilles’ heel for chemotherapy-resistant B-ALL
Relapse remains a major barrier to survival in B-cell acute lymphoblastic leukemia (B-ALL). Both activation of B-cell signaling pathways and increased glucose consumption have been linked to chemoresistance and relapse risk. In this study, we connect these observations by showing that B-ALL cells with active mTOR signaling, marked by high phosphorylated ribosomal protein S6 (pS6+), are glucose dependent. Isotope tracing confirms that pS6+ cells are highly glycolytic and rely on glucose for de novo nucleotide synthesis. Uridine, but not other purines or pyrimidines, rescue pS6+ cells from glucose deprivation, highlighting uridine as essential for survival. Active mammalian target of rapamycin (mTOR) signaling in pS6+ cells drives de novo pyrimidine synthesis by activating carbamoyl phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyzes the initial steps of de novo pyrimidine synthesis. Inhibiting signaling abolishes glucose dependency and CAD phosphorylation. Primary pS6+ cells express high levels of pyrimidine synthesis proteins, including dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in pyrimidine synthesis. Increased DHODH expression correlates with relapse and poor event-free survival. Most B-ALL molecular subtypes exhibit DHODH activity. BAY-2402234, a DHODH inhibitor, effectively kills pS6+ cells in vitro, with 50% inhibitory concentration values correlating with pS6 signaling strength across 14 xenografts derived from patients with B-ALL. In vivo, DHODH inhibition prolongs survival and reduces leukemia burden in pS6+ B-ALL models. Together, these findings link active signaling to pyrimidine dependency and relapse risk, highlighting DHODH inhibition as a promising therapeutic strategy for chemotherapy-resistant B-ALL.
- Open Access
Cell state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer
SUMMARY: Cellular heterogeneity and plasticity are hallmarks of cancer that contribute to tumor growth and therapy resistance. Here we investigated metabolic heterogeneity in small cell lung cancer (SCLC), an aggressive neuroendocrine (NE) cancer type. Through integrated transcriptomic and metabolomic analyses, we identified a universal dependency on exogenous cysteine/cystine (Cys) across all NE/non-NE SCLC cell states. Notably, NE and non-NE cells with low levels of the ASCL1 transcription factor die from ferroptosis upon Cys depletion. In contrast, ASCL1-high cells die from apoptosis but are ferroptosis resistant. This resistance to ferroptosis is driven by the direct upregulation of the gene coding for the GCH1 enzyme by ASCL1, which results in higher levels of the BH4/BH2 antioxidants. Accordingly, combining cysteine depletion with BH4/BH2 synthesis inhibition effectively reduces tumor growth in patient-derived xenografts. This work elucidates distinct metabolic states in SCLC and suggests new approaches to induce cell death in this lethal form of cancer.
Open AccessCell state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer
SUMMARY: Cellular heterogeneity and plasticity are hallmarks of cancer that contribute to tumor growth and therapy resistance. Here we investigated metabolic heterogeneity in small cell lung cancer (SCLC), an aggressive neuroendocrine (NE) cancer type. Through integrated transcriptomic and metabolomic analyses, we identified a universal dependency on exogenous cysteine/cystine (Cys) across all NE/non-NE SCLC cell states. Notably, NE and non-NE cells with low levels of the ASCL1 transcription factor die from ferroptosis upon Cys depletion. In contrast, ASCL1-high cells die from apoptosis but are ferroptosis resistant. This resistance to ferroptosis is driven by the direct upregulation of the gene coding for the GCH1 enzyme by ASCL1, which results in higher levels of the BH4/BH2 antioxidants. Accordingly, combining cysteine depletion with BH4/BH2 synthesis inhibition effectively reduces tumor growth in patient-derived xenografts. This work elucidates distinct metabolic states in SCLC and suggests new approaches to induce cell death in this lethal form of cancer.
- Open Access
- 12 March 2026
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-17
Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer
Objective: The mitochondrial serine catabolic pathway (MSCP) supports tumor proliferation and metastasis, yet no therapies target the MSCP. Because cancer cells rely on the MSCP when respiration is suppressed, we hypothesized that reactivating respiration would inhibit the MSCP. Methods: Mitochondrial respiration was activated in triple negative breast cancer (TNBC) cells using uncouplers [niclosamide ethanolamine (NEN) and BAM15]. Metabolic activity through the MSCP was assessed using U-13C-serine tracing and expression of key MSCP enzymes (SHMT2, MTHFD2, and MTHFD1L) were evaluated at the mRNA and protein levels. The NAD+:NADH ratio and 2-hydroxyglutarate (2-HG) levels were determined using liquid chromatography-mass spectrometry. The role of m6A RNA demethylase fat mass and obesity-associated protein (FTO) in regulating MSCP enzymes was examined using pharmacologic and genetic approaches. The therapeutic potential of mitochondrial uncoupling was tested in vivo using a lung metastasis model. Results: Activation of mitochondrial respiration with NEN or BAM15 inhibited MSCP activity, as indicated by reduced labeling of glycine and purines from U-13C-serine. Mitochondrial uncoupling markedly decreased the levels of SHMT2, MTHFD2, and MTHFD1L protein, despite unchanged or elevated mRNA levels. This post-transcriptional suppression was mediated by an increased NAD+:NADH ratio, leading to reduced 2-HG production and subsequent activation of FTO. Inhibition of FTO, either pharmacologically or genetically, restored MSCP enzyme protein levels. Dietary mitochondrial uncoupling significantly suppressed lung metastasis in vivo. Conclusions: The findings herein demonstrated that mitochondrial uncouplers inhibit MSCP through FTO-dependent m6A demethylation. This work identified mitochondrial uncoupling as a novel and promising therapeutic approach for promoting m6A demethylation and targeting MSCP in metastatic breast cancer.
- 12 March 2026
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-17
Open AccessMitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer
Objective: The mitochondrial serine catabolic pathway (MSCP) supports tumor proliferation and metastasis, yet no therapies target the MSCP. Because cancer cells rely on the MSCP when respiration is suppressed, we hypothesized that reactivating respiration would inhibit the MSCP. Methods: Mitochondrial respiration was activated in triple negative breast cancer (TNBC) cells using uncouplers [niclosamide ethanolamine (NEN) and BAM15]. Metabolic activity through the MSCP was assessed using U-13C-serine tracing and expression of key MSCP enzymes (SHMT2, MTHFD2, and MTHFD1L) were evaluated at the mRNA and protein levels. The NAD+:NADH ratio and 2-hydroxyglutarate (2-HG) levels were determined using liquid chromatography-mass spectrometry. The role of m6A RNA demethylase fat mass and obesity-associated protein (FTO) in regulating MSCP enzymes was examined using pharmacologic and genetic approaches. The therapeutic potential of mitochondrial uncoupling was tested in vivo using a lung metastasis model. Results: Activation of mitochondrial respiration with NEN or BAM15 inhibited MSCP activity, as indicated by reduced labeling of glycine and purines from U-13C-serine. Mitochondrial uncoupling markedly decreased the levels of SHMT2, MTHFD2, and MTHFD1L protein, despite unchanged or elevated mRNA levels. This post-transcriptional suppression was mediated by an increased NAD+:NADH ratio, leading to reduced 2-HG production and subsequent activation of FTO. Inhibition of FTO, either pharmacologically or genetically, restored MSCP enzyme protein levels. Dietary mitochondrial uncoupling significantly suppressed lung metastasis in vivo. Conclusions: The findings herein demonstrated that mitochondrial uncouplers inhibit MSCP through FTO-dependent m6A demethylation. This work identified mitochondrial uncoupling as a novel and promising therapeutic approach for promoting m6A demethylation and targeting MSCP in metastatic breast cancer.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S3. Mitochondrial uncoupler FCCP and BAM5 inhibit reductive carboxylation.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S3. Mitochondrial uncoupler FCCP and BAM5 inhibit reductive carboxylation.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S1. Mitochondrial uncoupler NEN increases cellular NAD+/NADH ratio and inhibits reductive carboxylation.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S1. Mitochondrial uncoupler NEN increases cellular NAD+/NADH ratio and inhibits reductive carboxylation.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S4. Mitochondrial uncoupler NEN inhibits reductive carboxylation under hypoxia.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S4. Mitochondrial uncoupler NEN inhibits reductive carboxylation under hypoxia.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S9. ETC inhibition only inhibits proliferation, but not spheroid formation, while Mitochondrial uncoupling inhibits both.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S9. ETC inhibition only inhibits proliferation, but not spheroid formation, while Mitochondrial uncoupling inhibits both.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S8. Mitochondrial uncoupling inhibits proliferation upon anchorage-independent growth.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S8. Mitochondrial uncoupling inhibits proliferation upon anchorage-independent growth.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S5. Mitochondrial uncoupler NEN, FCCP and BAM15 inhibit reductive carboxylation under hypoxia.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells
S5. Mitochondrial uncoupler NEN, FCCP and BAM15 inhibit reductive carboxylation under hypoxia.